| 1.73 -0.23 (-11.73%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.73 | 1-year : | 3.6 |
| Resists | First : | 2.33 | Second : | 3.08 |
| Pivot price | 1.59  |
|||
| Supports | First : | 1.12 | Second : | 0.93 |
| MAs | MA(5) : | 1.75  |
MA(20) : | 1.74 |
| MA(100) : | 6.84 |
MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 67.4 |
D(3) : | 58.1 |
| RSI | RSI(14): 39.9 |
|||
| 52-week | High : | 33.65 | Low : | 1.12 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LIMN ] has closed below upper band by 33.5%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 1.92 - 1.93 | 1.93 - 1.94 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.71 - 1.73 | 1.73 - 1.75 |
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
Wed, 04 Jun 2025
Liminatus Pharma Stock Surges to Record High After Regaining Nasdaq Compliance - Stocktwits
Fri, 02 May 2025
Liminatus Pharma, Inc. - Class A Common Stock (Nasdaq:LIMN) Stock Quote | FinancialContent - FinancialContent
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 79.4 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 312 (K) |
| Shares Short P.Month | 274 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -10.82 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -32.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|